Insmed Investor Presentation 2020 - ARIKAYCE

Insmed's February 2020 investor presentation detailing ARIKAYCE, their FDA-approved treatment for Mycobacterium avium complex lung disease in limited patient populations. The presentation covers commercialization progress, clinical data including the WILLOW study results, and regulatory pathway for expanded indications and full approval.